Drug
Tak 411
Tak 411: highest development phase Phase 2, developed by Takeda. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Takeda
Trials
| Drug | Phase | Indication |
|---|---|---|
| TAK-411 NCT06798012 | Phase 2 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) |
Latest
No recent events.
Follow Tak 411 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.